Daewoong Pharma's Nabota (botulinum toxin type A) has surpassed 1 trillion won (approximately $750M USD) in annual sales, marking a milestone for the South Korean manufacturer as it accelerates global market expansion. Nabota competes with Botox, Dysport, and Jeuveau across medspas, dermatology practices, and surgical centers worldwide.
Injectables
Daewoong Pharma's Nabota Exceeds 1 Trillion Won in Sales, Accelerates Global Push
South Korean neuromodulator maker scales international distribution as price competition intensifies.
Nabota's 1 trillion won milestone reflects global neuromodulator commoditization and intensifying price competition.
Nabota's scale and pricing advantage—particularly in markets outside North America—create competitive pressure on incumbent neuromodulator suppliers. For U.S. medspas, Nabota's growth signals the maturation of the global neuromodulator market and the likelihood of continued price compression. Practices should evaluate Nabota's availability, rebate structure, and clinical equivalence data if considering portfolio diversification. The broader implication: neuromodulator commoditization is accelerating, making differentiation through complementary services (RF, fillers, biostimulators) increasingly critical to practice margins.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.